Log in
NASDAQ:ABUS

Arbutus Biopharma Stock Forecast, Price & News

$3.14
+0.16 (+5.37 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.97
Now: $3.14
$3.19
50-Day Range
$2.37
MA: $3.17
$4.37
52-Week Range
$0.82
Now: $3.14
$9.02
Volume3.75 million shs
Average Volume2.40 million shs
Market Capitalization$260.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Read More
Arbutus Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABUS
CUSIPN/A
Phone267-469-0914

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.01 million
Book Value($1.00) per share

Profitability

Net Income$-153,720,000.00
Net Margins-1,751.83%

Miscellaneous

Employees79
Market Cap$260.34 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$3.14
+0.16 (+5.37 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

How has Arbutus Biopharma's stock been impacted by COVID-19?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABUS shares have increased by 21.7% and is now trading at $3.14.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Arbutus Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arbutus Biopharma
.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Corp (NASDAQ:ABUS) issued its quarterly earnings data on Friday, August, 7th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01. The biopharmaceutical company earned $1.51 million during the quarter, compared to the consensus estimate of $1.85 million.
View Arbutus Biopharma's earnings history
.

What price target have analysts set for ABUS?

6 Wall Street analysts have issued 12 month price targets for Arbutus Biopharma's stock. Their forecasts range from $4.00 to $8.00. On average, they expect Arbutus Biopharma's share price to reach $5.80 in the next twelve months. This suggests a possible upside of 84.7% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65)

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (2.06%), Hudson Bay Capital Management LP (1.21%), Bank of Montreal Can (0.58%), Jennison Associates LLC (0.49%), UBS Group AG (0.47%) and Two Sigma Advisers LP (0.20%).
View institutional ownership trends for Arbutus Biopharma
.

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of Montreal Can, UBS Group AG, and Jennison Associates LLC.
View insider buying and selling activity for Arbutus Biopharma
.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was acquired by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Russell Investments Group Ltd., Jane Street Group LLC, Creative Planning, Two Sigma Advisers LP, and Virtu Financial LLC.
View insider buying and selling activity for Arbutus Biopharma
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $3.14.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $260.34 million and generates $6.01 million in revenue each year. The biopharmaceutical company earns $-153,720,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at 267-469-0914 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.